Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
As breast cancer survival is increased by the diagnosis of earlier-stage disease and treatments improve, the side effects of cancer treatments, such as cardiotoxicity, remain clinically important. Although physicians have known for 30 years that anthracyclines cause acute and chronic cardiotoxicity, the cardiotoxic effects of radiation therapy, hormonal therapy (including tamoxifen and the aromatase inhibitors), and chemotherapy with taxanes and trastuzumab treatment have emerged more recently. This review examines the cardiac toxicity of adjuvant therapy, monitoring for early changes and existing guidelines for monitoring cardiac function in patients with breast cancer.
Bird
Brian R J Healey
BR
Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, MD, USA.
Swain
Sandra M
SM
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006321:Heart / Q000187:drug effects / Q000528:radiation effects; D006331:Heart Diseases / Q000209:etiology* / Q000503:physiopathology*; D006801:Humans; D011878:Radiotherapy / Q000009:adverse effects*; D017741:Survivors
D000970:Antineoplastic Agents